Description

Velpanat (Sofosbuvir/Velpatasvir)

About Velpanat

Velpanat is a prescription medication containing the active ingredients Sofosbuvir and Velpatasvir. It belongs to the class of antiviral medications, specifically hepatitis C virus (HCV) treatment. Velpanat is designed to help patients with chronic HCV infection achieve a sustained virologic response (SVR), which is considered a cure.

Composition

Velpanat contains the following active and inactive ingredients:

* Sofosbuvir: 400 mg
* Velpatasvir: 100 mg
* Microcrystalline cellulose
* Croscarmellose sodium
* Colloidal silicon dioxide
* Magnesium stearate
* Film coating: Opadry II 35K040040 (hypromellose, lactose monohydrate, titanium dioxide, and triacetin)

Uses / Indications

Velpanat is indicated for the treatment of the following conditions:

* Chronic hepatitis C virus (HCV) infection in adults and children aged 3 years and older, including those with:
+ Genotype 1, 2, 3, 4, 5, or 6 HCV infection
+ Compensated cirrhosis
+ Decompensated cirrhosis
+ Severe fibrosis
* Chronic HCV infection in patients coinfected with HIV-1
* Chronic HCV infection in patients with end-stage renal disease (ESRD) undergoing dialysis

How It Works (Mechanism of Action)

Velpanat works by targeting the HCV virus at multiple stages of its life cycle. Sofosbuvir inhibits the NS5B polymerase enzyme, which is essential for viral replication, while Velpatasvir targets the NS5A protein, which plays a critical role in viral replication and survival. By inhibiting these enzymes, Velpanat helps to reduce the amount of HCV virus in the body and promote a sustained virologic response.

Dosage & Administration

Velpanat should be taken orally once daily with or without food. The recommended dosage for adults and children aged 3 years and older is:

* 1 tablet (400 mg Sofosbuvir + 100 mg Velpatasvir) taken once daily
* Treatment duration: 12 weeks for most patients; 24 weeks for patients with genotype 3 HCV infection
* Patients with severe renal impairment or end-stage renal disease (ESRD) should receive a reduced dose of Sofosbuvir (200 mg) once daily

Side Effects

Common side effects of Velpanat (reported in ≥10% of patients) include:

* Headache
* Fatigue
* Nausea
* Diarrhea
* Abdominal pain

Serious side effects of Velpanat (reported in <1% of patients) include:

* Anemia
* Leukopenia
* Thrombocytopenia
* Hepatitis B reactivation
* Pancreatitis
* Severe hypersensitivity reactions

Warnings & Precautions

Velpanat should be used with caution in patients with:

* Pregnancy or breastfeeding
* HIV-1 coinfected patients
* Patients with severe renal impairment or ESRD
* Patients with severe liver disease
* Patients with a history of pancreatitis
* Patients with a history of severe hypersensitivity reactions

Velpanat should not be used in patients with:

* Hepatitis B virus (HBV) infection
* Severe hypersensitivity reactions to Sofosbuvir or Velpatasvir
* Severe renal impairment or ESRD with hemodialysis

Contraindications

Velpanat is contraindicated in patients with:

* Hepatitis B virus (HBV) infection
* Severe hypersensitivity reactions to Sofosbuvir or Velpatasvir
* Severe renal impairment or ESRD with hemodialysis

Drug Interactions

Velpanat may interact with:

* Warfarin
* Rifampin
* Carbamazepine
* Phenytoin
* St. John’s Wort
* Atazanavir
* Darunavir
* Efavirenz
* Enfuvirtide
* Indinavir
* Lopinavir
* Nelfinavir
* Ritonavir
* Saquinavir
* Tipranavir

Missed Dose & Overdose

If a dose of Velpanat is missed, it should be taken as soon as possible. However, if the next scheduled dose is less than 6 hours away, the missed dose should be skipped.

In case of overdose, patients should seek medical attention immediately.

Storage Instructions

Velpanat should be stored at room temperature (20°C to 25°C or 68°F to 77°F) in a dry place, away from light.

Conclusion

Velpanat is a prescription medication that has been shown to be effective in treating chronic hepatitis C virus (HCV) infection. By targeting the HCV virus at multiple stages of its life cycle, Velpanat helps to reduce the amount of HCV virus in the body and promote a sustained virologic response. If you have any questions or concerns about Velpanat, please consult your doctor or pharmacist. They can help you determine if Velpanat is right for you and provide guidance on how to use it safely and effectively.

Frequently Asked Questions (FAQs)

Q: What is the recommended dosage of Velpanat for adults?

A: The recommended dosage of Velpanat for adults is 1 tablet (400 mg Sofosbuvir + 100 mg Velpatasvir) taken once daily with or without food.

Q: Can Velpanat be taken with other medications?

A: Velpanat may interact with other medications, including warfarin, rifampin, carbamazepine, and others. Your doctor or pharmacist can help you determine if it is safe to take Velpanat with other medications.

Q: What are the side effects of Velpanat?

A: Common side effects of Velpanat include headache, fatigue, nausea, diarrhea, and abdominal pain. Serious side effects of Velpanat include anemia, leukopenia, thrombocytopenia, hepatitis B reactivation, pancreatitis, and severe hypersensitivity reactions.

Q: Can Velpanat be used in patients with HIV-1 coinfected with HCV?

A: Yes, Velpanat can be used in patients with HIV-1 coinfected with HCV. However, patients with HIV-1 coinfected with HCV should be treated with caution and under the close supervision of a healthcare provider.

Q: How long does treatment with Velpanat typically last?

A: Treatment with Velpanat typically lasts 12 weeks for most patients. Patients with genotype 3 HCV infection may require 24 weeks of treatment.

Q: Can Velpanat be taken by patients with severe renal impairment or ESRD?

A: Yes, Velpanat can be taken by patients with severe renal impairment or ESRD. However, patients with severe renal impairment or ESRD should receive a reduced dose of Sofosbuvir (200 mg) once daily.